PL EN
REVIEW PAPER
Effect of selected environmental factors on development of non-small cell lung cancer
 
More details
Hide details
1
Regionalne Centrum Naukowo-Technologiczne, Polska
 
 
Corresponding author
Kacper Szafraniec   

Regionalne Centrum Naukowo-Technologiczne, Podzamcze 45, 25-636, Chęciny, Polska
 
 
Med Srod. 2024;27(2):46-50
 
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Cancer is one of the major health problems today. In Poland, mortality due to cancer remains at 260 deaths per 100,000 population per year, and lung cancer accounts for the highest number of cancer deaths in men and women. Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases. The purpose of this review is to examine the effects of relevant environmental factors, such as smoking tobacco products, arsenic, beta-carotene, bisphenol A and atmospheric aerosols with a diameter smaller than 2.5 μm on the carcinogenesis of non-small cell lung cancer. By analyzing exposure to these substances, the study aims to highlight the need to reduce plastic production and seek alternatives to environmentally harmful human activities, including fuel combustion. The review article is based on a systematic analysis of scientific research in the field of non-small cell lung cancer. Existing research on environmental factors affecting the development of NSCLC was analyzed.

Abbreviated description of the state of knowledge:
Analysis of the incidence of NSCLC has revealed the importance of conducting research on environmental factors. This is emphasized by findings showing that smoking tobacco products, beta-carotene supplementation, and exposure to PM 2.5, bisphenol A and arsenic increase the risk of metastatic potential. Arsenic in the form of nitric trioxide (ATO) may also have beneficial effects. ATO supply reduces the proliferation of gefitinib-resistant NSCLC tumour cells and inhibits EGFR kinase activity.

Summary:
Advances in knowledge of NSCLC factors are leading to therapeutic discoveries and emphasize the need for prevention of risk factors.

REFERENCES (20)
1.
Główny Urząd Statystyczny. Raport 2020 – Polska Na Drodze Zrównoważonego Rozwoju; 2020. Accessed January 30, 2024. https://raportsdg.stat.gov.pl/....
 
2.
Fan Y, Jiang Y, Gong L, et al. Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019. Front Public Health. 2023;11. doi:10.3389/fpubh.2023.1054200.
 
3.
Folesani G, Galetti M, Petronini PG, et al. Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review. Int J Environ Res Public Health. 2023;20(5). doi:10.3390/ijerph20054167.
 
4.
Padinharayil H, Varghese J, John MC, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2023;10(3):960–989. doi:10.1016/j.gendis.2022.07.023.
 
5.
Padinharayil H, Varghese J, John MC, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2023;10(3):960–98.
 
6.
Nail AN, Ferragut Cardoso AP, Montero LK, States JC. miRNAs and arsenic-induced carcinogenesis. In: Advances in Pharmacology. Vol 96. Academic Press Inc.; 2023:203–240. doi:10.1016/bs.apha.2022.10.002.
 
7.
Schmidlin CJ, Zeng T, Liu P, et al. Chronic arsenic exposure enhances metastatic potential via NRF2-mediated upregulation of SOX9. Toxicol Appl Pharmacol. 2020;402. doi:10.1016/j.taap.2020.115138.
 
8.
Mao J, Ma L, Shen Y, et al. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. Cell Death Dis. 2018;9(10). doi:10.1038/s41419-018-0998-7.
 
9.
Padinharayil H, Varghese J, John MC, et al. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 2023;10(3):960.
 
10.
Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937–970. doi:10.1002/cac2.12359.
 
11.
Połtyn-Zaradna K, Psikus P, Zatońska K. Changes in Attitudes toward Tobacco Smoking and Factors Associated with Quitting in 9-Year Observation of PURE Poland Cohort Study. Int J Environ Res Public Health. 2022;19(11). doi:10.3390/ijerph19116564.
 
12.
Inadera H. Neurological effects of bisphenol A and its analogues. Int J Med Sci. 2015;12(12):926–936. doi:10.7150/ijms.13267.
 
13.
vom Saal FS, Vandenberg LN. Update on the Health Effects of Bisphenol A: Overwhelming Evidence of Harm. Endocrinology. 2021;162(3). doi:10.1210/endocr/bqaa171.
 
14.
Maitra R, Malik P, Mukherjee TK. Targeting estrogens and various estrogen-related receptors against non-small cell lung cancers: A perspective. Cancers (Basel). 2022;14(1). doi:10.3390/cancers14010080.
 
15.
Bae S, Lim JW, Kim H. β-Carotene Inhibits Expression of Matrix Metalloproteinase-10 and Invasion in Helicobacter pylori-Infected Gastric Epithelial Cells. Molecules. 2021;26(6). doi:10.3390/molecules26061567.
 
16.
Ellwood K. (2007). December 5, 2007. https://www.cspinet.org/sites/....
 
17.
Kordiak J, Bielec F, Jabłoński S, Pastuszak-Lewandoska D. Role of Beta-Carotene in Lung Cancer Primary Chemoprevention: A Systematic Review with Meta-Analysis and Meta-Regression. Nutrients. 2022;14(7). doi:10.3390/nu14071361.
 
18.
Holme JA, Vondráček J, Machala M, et al. Lung cancer associated with combustion particles and fine particulate matter (PM2.5) – The roles of polycyclic aromatic hydrocarbons (PAHs) and the aryl hydro-carbon receptor (AhR). Biochem Pharmacol. 2023;216. doi:10.1016/j.bcp.2023.115801.
 
19.
Santibáñez-Andrade M, Chirino YI, González-Ramírez I, Sánchez-Pérez Y, García-Cuellar CM. Deciphering the code between air pollution and disease: The effect of particulate matter on cancer hallmarks. Int J Mol Sci. 2020;21(1). doi:10.3390/ijms21010136.
 
20.
Chen Q, Wang Y, Yang L, et al. PM2.5 promotes NSCLC carcinogenesis through translationally and transcriptionally activating DLAT-mediated glycolysis reprograming. Journal of Experimental and Clinical Cancer Research. 2022;41(1). doi:10.1186/s13046-022-02437-8.
 
eISSN:2084-6312
ISSN:1505-7054
Journals System - logo
Scroll to top